228 research outputs found
Morphological instability at topological defects in a three-dimensional vertex model for spherical epithelia
Epithelial monolayers are a central building block of complex organisms.
Topological defects have emerged as important elements for single cell behavior
in flat epithelia. Here we theoretically study such defects in a
three-dimensional vertex model for spherical epithelia like cysts or intestinal
organoids. We find that they lead to the same generic morphological instability
to an icosahedral shape as it is known from spherical elastic shells like virus
capsids, polymerized vesicles or buckyballs. We derive analytical expressions
for the effective stretching and bending moduli as a function of the parameters
of the vertex model, in excellent agreement with computer simulations. These
equations accurately predict both the buckling of a flat epithelial monolayer
under uniaxial compression and the faceting transition around the topological
defects in spherical epithelia. We further show that localized apico-basal
tension asymmetries allow them to reduce the transition threshold to small
system sizes.Comment: 5 pages, 5 figures, supplemental materia
Precision mass measurements of magnesium isotopes and implications on the validity of the Isobaric Mass Multiplet Equation
If the mass excess of neutron-deficient nuclei and their neutron-rich mirror
partners are both known, it can be shown that deviations of the Isobaric Mass
Multiplet Equation (IMME) in the form of a cubic term can be probed. Such a
cubic term was probed by using the atomic mass of neutron-rich magnesium
isotopes measured using the TITAN Penning trap and the recently measured
proton-separation energies of Cl and Ar. The atomic mass of
Mg was found to be within 1.6 of the value stated in the Atomic
Mass Evaluation. The atomic masses of Mg were measured to be both
within 1, while being 8 and 34 times more precise, respectively. Using
the Mg mass excess and previous measurements of Cl we uncovered a
cubic coefficient of = 28(7) keV, which is the largest known cubic
coefficient of the IMME. This departure, however, could also be caused by
experimental data with unknown systematic errors. Hence there is a need to
confirm the mass excess of S and the one-neutron separation energy of
Cl, which have both come from a single measurement. Finally, our results
were compared to ab initio calculations from the valence-space in-medium
similarity renormalization group, resulting in a good agreement.Comment: 7 pages, 3 figure
EXCITED STATE ABSORPTION AND THERMOLUMINESCENCE IN Ce AND Mg DOPED YTTRIUM ALUMINUM GARNET*
In this paper we report preliminary results of optical studies on Y3 Al5012 (YAG) crystals codoped with Ce and Mg. By using measurements of luminescence, absorption, and luminescence excitation spectra we demonstrate that although the basic features introduced to the YAG host by the Ce-doping remain intact, the Mg-codoping imposes some significant changes on other properties of the material. These changes are potentially important for laser and/or scintillator applications of YAG:Ce and are due, most likely, to modifications of defect populations in the material. We characterize them by using the techniques of thermoluminescence and excited state absorption under excimer laser pumping. These techniques, interestingly, yield results that seem inconsistent. While the thermoluminescence signal of the Mg-doped sample is strongly reduced, suggesting that trap concentrations in the presence of Mg are suppressed, the excited state absorption signal, which we also relate to the traps, is higher. We offer a tentative explanation of this contradiction between the two experiments that involves a massive transfer of electrons from the Mg-related defects to the excited state absorption centers caused by the excimer pump itself
Combined CI+MBPT calculations of energy levels and transition amplitudes in Be, Mg, Ca, and Sr
Configuration interaction (CI) calculations in atoms with two valence
electrons, carried out in the V(N-2) Hartree-Fock potential of the core, are
corrected for core-valence interactions using many-body perturbation theory
(MBPT). Two variants of the mixed CI+MBPT theory are described and applied to
obtain energy levels and transition amplitudes for Be, Mg, Ca, and Sr
Increasing transnational sea‐ice exchange in a changing Arctic Ocean
The changing Arctic sea‐ice cover is likely to impact the trans‐border exchange of sea ice between the exclusive economic zones (EEZs) of the Arctic nations, affecting the risk of ice‐rafted contamination. We apply the Lagrangian Ice Tracking System (LITS) to identify sea‐ice formation events and track sea ice to its melt locations. Most ice (52%) melts within 100 km of where it is formed; ca. 21% escapes from its EEZ. Thus, most contaminants will be released within an ice parcel's originating EEZ, while material carried by over 1 00,000 km2 of ice—an area larger than France and Germany combined—will be released to other nations' waters. Between the periods 1988–1999 and 2000–2014, sea‐ice formation increased by ∼17% (roughly 6 million km2 vs. 5 million km2 annually). Melting peaks earlier; freeze‐up begins later; and the central Arctic Ocean is more prominent in both formation and melt in the later period. The total area of ice transported between EEZs increased, while transit times decreased: for example, Russian ice reached melt locations in other nations' EEZs an average of 46% faster while North American ice reached destinations in Eurasian waters an average of 37% faster. Increased trans‐border exchange is mainly a result of increased speed (∼14% per decade), allowing first‐year ice to escape the summer melt front, even as the front extends further north. Increased trans‐border exchange over shorter times is bringing the EEZs of the Arctic nations closer together, which should be taken into account in policy development—including establishment of marine‐protected areas
Calculations of collisions between cold alkaline earth atoms in a weak laser field
We calculate the light-induced collisional loss of laser-cooled and trapped
magnesium atoms for detunings up to 50 atomic linewidths to the red of the
^1S_0-^1P_1 cooling transition. We evaluate loss rate coefficients due to both
radiative and nonradiative state-changing mechanisms for temperatures at and
below the Doppler cooling temperature. We solve the Schrodinger equation with a
complex potential to represent spontaneous decay, but also give analytic models
for various limits. Vibrational structure due to molecular photoassociation is
present in the trap loss spectrum. Relatively broad structure due to absorption
to the Mg_2 ^1Sigma_u state occurs for detunings larger than about 10 atomic
linewidths. Much sharper structure, especially evident at low temperature,
occurs even at smaller detunings due to of Mg_2 ^1Pi_g absorption, which is
weakly allowed due to relativistic retardation corrections to the forbidden
dipole transition strength. We also perform model studies for the other
alkaline earth species Ca, Sr, and Ba and for Yb, and find similar qualitative
behavior as for Mg.Comment: 20 pages, RevTex, 13 eps figures embedde
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen
- …